glimepiride has been researched along with Idiopathic Parkinson Disease in 2 studies
glimepiride: structure given in first source
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Oduola-Akande, MD | 1 |
| Ishola, IO | 1 |
| Olubodun-Obadun, TG | 1 |
| Akande, AJ | 1 |
| Adeyemi, OO | 1 |
| Lietzau, G | 1 |
| Magni, G | 1 |
| Kehr, J | 1 |
| Yoshitake, T | 1 |
| Candeias, E | 1 |
| Duarte, AI | 1 |
| Pettersson, H | 1 |
| Skogsberg, J | 1 |
| Abbracchio, MP | 1 |
| Klein, T | 1 |
| Nyström, T | 1 |
| Ceruti, S | 1 |
| Darsalia, V | 1 |
| Patrone, C | 1 |
2 other studies available for glimepiride and Idiopathic Parkinson Disease
| Article | Year |
|---|---|
Glimepiride Prevents 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine Induced Dopamine Neurons Degeneration Through Attenuation of Glia Activation and Oxidative Stress in Mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Diabetes Mellitus, Type 2; Disease Models, An | 2023 |
Dipeptidyl peptidase-4 inhibitors and sulfonylureas prevent the progressive impairment of the nigrostriatal dopaminergic system induced by diabetes during aging.
Topics: Aging; Animals; Corpus Striatum; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Dise | 2020 |